Bronkhorst opens new UK premises
Move to Newmarket offers scope for expansion
A wholly owned subsidiary of Bronkhorst High-Tech BV of Holland, the company was established in Sawston, Cambridgeshire in 2002, since when it claims to have increased turnover by 800%.
Having outgrown its original headquarters, the company has relocated to Newmarket in order to have room for future expansion and gain access to the local pool of skilled labour. There are plans to double the workforce within the next five years.
To mark the occasion, Councillor Mick Jeffrys, the Mayor of Newmarket, performed the official opening. Special guests included the joint founders and co-owners of Bronkhorst, Teus Bruggemann and Wybren Jouwsma, who have invested substantially in growing the UK operation and have a policy of investing around 15% of group annual turnover on r&d.
Bronkhorst UK’s managing director Andrew Mangell, said: ‘We have grown rapidly in terms of both sales revenue and staff numbers, even maintaining an upward trend during the recession, and our new Newmarket base gives us more valuable floorspace, good links with the travel network and a superb quality of environment.’
Bronkhorst claims to supply virtually every customer sector in the UK, taking in laboratory, university, industrial, pilot plant and hazardous area applications.
You may also like
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model